9th Annual Conference of International Liver Cancer Association
Paris Marriot Rive Gauche Hotel & Conference CenterParis, FRANCE Visit the Venue to read more
Dear ILCA members, colleagues and friends,
We are very pleased to invite you to attend the 9th Annual Conference of the International Liver Cancer Association (ILCA), which will be held on 4–6 September 2015 at the Paris Marriott Rive Gauche Hotel & Conference Center in Paris.
Since its creation and inaugural conference in 2007, ILCA has grown steadily and successfully organised conferences to all parts of the world, with the sole aim to contribute to advancing liver cancer science and care worldwide.
ILCA 2014 in Kyoto, Japan, welcomed 700 participants from 44 different countries and proved to be a great success!
ILCA is excited to bring its 9th Annual Conference to the beautiful and fascinating city of Paris, and to offer liver cancer experts an international multidisciplinary forum to exchange the latest innovations in research and care.
The multidisciplinary programme of ILCA 2015 will feature:
State-of-the-Art Lectures offered by distinguished colleagues within the field
Symposia focusing on the cutting edge advancements on the research and treatment levels, incorporating a truly international panel of speakers
General Sessions and e-Poster Viewing Tours that will deliver the latest breaking research from among the abstracts submitted to the conference
Luncheon Workshops offered by the most knowledgeable HCC experts in highly interactive sessions
Networking Breaks and Reception
Plus! Pre-Conference Workshop on Immunopathogenesis and Immunotherapy in HCC
ILCA 2015 will also provide you with numerous opportunities to network and connect with your peers from all over the world during breaking sessions, lunches and the welcome reception.
We look forward to welcoming you to Paris at this multidisciplinary and international event to learn, share, network and advance liver cancer science and care with us.
The ILCA Governing Board
President Peter R. Galle (Germany)
Executive Secretary Riccardo Lencioni (Italy)
Treasurer Morris Sherman (Canada)
President Elect Richard Finn (USA)
Ann-Lii Cheng (Taiwan)
Norihiro Kokudo (Japan)
Ronnie Poon (P.R. China)
Peter Schirmacher (Germany)
Myron Schwartz (USA)
Xin Wei Wang* (USA)
Jessica Zucman-Rossi (France)
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
e-Posters and Paper posters
Even in 2015, ILCA will continue with the use of e-Posters in the scientific programme of the 9th Annual Conference. e-Posters have completely replaced the printed posters. Authors will have the opportunity to prepare a number of slides, which will be displayed on touch screens throughout the ILCA 2015 Conference.
Two specific e-Poster Viewing Tours will be held on Saturday, 5 September 2015 and will be partly focusing on 15 top-scored abstracts within each session, which will be showed in a form of e-Poster as well as on a static panel as paper board poster. Both of the tours will be opened by one of the ILCA prominent scientists.
e-Poster/Paper poster preparation and submission
e-Poster/Paper poster presenters will receive an email with instructions on where and how to submit their e-Poster/Paper poster presentation following acceptance of their abstract.
What is an e-Poster?
An e-Poster stands for electronic poster. Delegates can view e-Posters on interactive touch-screens.
What is the advantage of an e-Poster?
With this system, you can show a lot more information than on ordinary paper posters. The goal of this system is to be author and viewer-friendly, as well as innovative. Poster presenters no longer have to pay relatively high sums to have their paper posters printed, and they no longer have to take large and cumbersome poster tubes with them to (international) events.
How do I prepare an e-Poster?
Presenters simply have to upload a PowerPoint presentation and the poster is ready to be viewed, no more poster boards and expensive printing costs. e-Posters have to be prepared in a PowerPoint file (97-2003, 2007, or later, using the default slide size) and should not exceed 10 slides. The total file size should not exceed 15 Mb. Videos can be included, but should also have a maximum size of 15 Mb each.
ILCA warmly thanks all Partners and Sponsors for their unrestricted support to the 2015 Annual Conference and their commitment to help advance liver cancer science.
If you wish to partner with ILCA around the 9th Annual Conference, please contact Tanguy Roelens at email@example.com. For media partnership, please contact firstname.lastname@example.org.
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer’s oncology franchise now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of RCW breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has three platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas™, TheraSilence™ and RAST ™.
International Liver Cancer Association (ILCA)
Avenue de Tervueren, 300
+32 (0)2 789 2345
+32 (0)2 743 1550